Metabolism Disorder TRIZ Cases

A PEGylated tissue kallikrein conjugated to the N-terminal primary amino group extends circulation half-life and retains biological activity.

RARbeta agonists reduce hepatic steatosis and inflammation while preserving beta-cell function in type 2 diabetes.

Chimeric FGF2/FGF1 proteins lower blood glucose levels while avoiding weight gain and liver toxicity associated with thiazolidinediones.

Shogaols modulate hepcidin levels to regulate iron metabolism, avoiding nephrotoxicity and liver damage caused by synthetic chelators.

Phospholipase modification of milk lecithin restores emulsion stability lost during protein hydrolysis, enabling hypoallergenic infant formulas.

Alkylglycoside surfactants prevent protein aggregation in concentrated formulations, reducing immunogenicity and eliminating cold chain storage requirements.

Neorogioldiol diterpene inhibits adipocyte differentiation and exhausts glycolytic capacity in metabolic models.

Local intestinal PKD2 inhibition reduces fat absorption, improving glucose tolerance and preventing atherosclerosis without systemic side effects.

A 30 to 120 minute infusion protocol reduces immune response and injection site reactions while maintaining treatment efficacy.

Human antibodies targeting FGFR4 epitopes reduce immunogenicity while maintaining high specificity and anti-tumor activity.

Hex-4-inoic acid derivative activates GPR40 receptors to promote glucose-dependent insulin secretion, avoiding hypoglycemia risks.

Lunasin peptides inhibit histone H3 acetylation to increase LDL receptor expression.

Anti-CXCL13 antibodies bind specific epitopes to block chemokine signaling pathways.

A recombinant acid alpha-glucosidase formulation maintains enzyme activity and concentration through specific pH buffering and excipient selection.

Mechanical stress deforms polymer particles into a continuous film on active pharmaceutical ingredients.

Lipid nanoparticle delivery of polynucleotides encoding methylmalonyl-CoA mutase restores metabolic function to treat methylmalonic acidemia.

Silicon oxide coatings on glass vials reduce aluminum toxicity in concentrated potassium phosphate injections while preventing visible particulate formation.

Lipid constructs target insulin to hepatocytes, resolving the trade-off between sustained release and liver-specific delivery.

Non-natural peptides modulate cannabinoid receptors without crossing the hematoencephalic barrier, eliminating psychiatric side effects.

Merges FGF-21 and GLP-1 compounds to treat obesity, addressing ineffective single-agent therapies.

Lipid nanoparticle encapsulation delivers modified mRNA encoding PCCA and PCCB, restoring enzyme activity while minimizing immune activation.

Segmented polypeptide sequences activate renal receptors to boost natriuresis without causing systemic hypotension.

Acylation at specific positions creates selective signaling that lowers glucose without over-stimulating lipid metabolism pathways.

Streptococcus gordonii metabolites reduce periodontal inflammation and promote microbial symbiosis, addressing low surgical success rates in obese patients.

Humulus japonicus extract replaces synthetic drugs to treat obesity and fatty liver without side effects.

Aromatic boron compounds orient functional groups to bind glucose selectively, resolving the trade-off between binding affinity and selectivity.

PEG-conjugated truncated uricase reduces immunogenicity while maintaining uricolytic activity to manage hyperuricemia.

Truncated PYY analogs with polyethylene glycol modifications improve synthesis ease while maintaining potency against Y2 receptors.

Red Yeast Rice extract combined with omega-3 polyunsaturated fatty acids overcomes lovastatin solubility limits via cyclodextrin inclusion complexes.

Zinc-charged insulin replaces surface ions with a protective ion cloud to survive stomach acid and enable gastrointestinal absorption.

Oil palm phenolics down-regulate cholesterol biosynthesis to attenuate inflammatory responses from atherogenic diets.

Peptide-bound glutamine retains bioavailability during retort processing, preventing degradation and ammonia accumulation.

Modified CDR sequences increase anti-GFRAL antibody binding affinity, blocking GDF15 signaling to mitigate cancer cachexia and chemotherapy side effects.

Conjugating fatty acids to urocortin-2 peptides extends circulation half-life, enabling once-weekly dosing for diabetes and chronic kidney disease treatment.

An oral polymer carrier expands in the stomach to reduce gastric volume using a programmable timer and radio frequency decoupling mechanism.

PEG conjugation extends calcimimetic half-life, reducing hypocalcemia risk and drug-drug interactions.

Specific amino acid substitutions in exendin-4 lower hypoglycemia risk by reducing GIP activity, extending duration of action for metabolic disorder treatment.

Combining HMB and ATP mitigates performance decline from overreaching while increasing strength and muscle mass.

Novel antibody conjugates targeting the glucose-dependent insulinotropic polypeptide receptor modulate metabolic activity through precise binding mechanisms.

Weekly exendin-4 microparticles maintain plasma levels to reduce weight while sparing lean body mass during caloric restriction.

A Lactobacillus probiotic composition modulates gut-brain signaling to improve appetite control and psychological well-being.

Insulin B-chain adjuvanted vaccine induces regulatory T cells, suppressing autoimmune beta cell destruction and preserving residual function.